MACRA, MIPS and DQSA: Unpacking the Acronyms and What They Mean for Ophthalmologists

Ophthalmology
Curriculum:
Market Access Challenges in Retinal Disease
Credits:
0.5 AMA PRA Category 1 Credit(s)™
Launch Date:
July 31, 2018
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Ophthalmologists involved in the treatment and management of patients with retina disorders.

Relevant Terms:

age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO)

David Eichenbaum, MD

David Eichenbaum, MD
Clinical Assistant Professor, Department of Ophthalmology
University of South Florida College of Medicine
Retina Vitreous Associates of Florida
Tampa, Florida

Dr. Eichenbaum is a board certified ophthalmologist fellowship-trained in diseases and surgery of the vitreous and retina. He 
has been practicing in Tampa Bay since 2007 and was born in St. Petersburg. He completed the Medical Honors Program completing his undergraduate and medical degree at the University of South Florida in Tampa. He completed his Ophthalmology residency at
the University of South Florida as well where he served as Chief Resident. Dr. Eichenbaum completed his two year Surgical Retina fellowship at Tufts New England Eye Center and Ophthalmic Consultants of Boston.
 
Dr. Eichenbaum has published in numerous professional journals, textbook chapters, and has presented his work at the American Society of Retinal Specialists, American Academy of Ophthalmology, and the Association of Research and Vision in Ophthalmology meeting. He speaks nationally on molecular eye medications for diseases such as macular degeneration, retinal vascular occlusions and diabetes, and has served on numerous Clinical Advisory Boards. Dr. Eichenbaum is Principal Investigator for multiple clinical trials in the practice dealing with diabetic and macular degenerative disease.
 
Dr. Eichenbaum is a Fellow of the American Academy of Ophthalmology, sits on the Board of the Florida Society of Ophthalmology, and has served as Past President of the Tampa Bay Ophthalmic Society. In 2015, he received Michael R. Redmond, MD Outstanding Young Ophthalmologist Award from the Florida Society of Ophthalmology. He is a member of the American Society of Retina Specialists, the Vit-Buckle Society, Club Vit, the Florida Society of Ophthalmology, and the Tampa Bay Society of Ophthalmology.
 
Dr. Eichenbaum has been a Clinical Assistant Professor of Ophthalmology at the University of South Florida since 2007 and co-chairs a monthly retina conference for the residency with Dr. Cohen.
 
Dr. Eichenbaum has clinics primarily in our Clearwater and St. Petersburg offices. He performs surgery at Largo Medical Center, St. Anthony's Physician's Surgery Center, and All Children's Hospital.
 

Jonathan L. Prenner, MD

Jonathan L. Prenner, MD
Clinical Professor and Chairman
Department of Ophthalmology
Rutgers Robert Wood Johnson Medical School
New Brunswick, NJ

Dr. Jonathan L. Prenner holds a number of leadership positions in the field of vitreoretinal surgery. Dr. Prenner is Chairman of the Department of Ophthalmology at Rutgers Robert Wood Johnson Medical School where he serves as Clinical Professor. He is also the Ophthalmology service chief of the Robert Wood Johnson University Hospital. Dr. Prenner is the Chairman of Education and a member of the executive committee for the American Society of Retinal Specialists (ASRS), the world's largest society of retinal specialists. He serves as both the Review Article Section Editor and Assistant Editor of the standard scientific journal for the field, RETINA: the Journal of Retina and Vitreous Diseases. He founded the journal New Retina MD and hosts the Retina Today Video Journal Club. He has been elected by his peers for inclusion in Best Doctors in America since 2008, is listed as a U.S. News and Castle Connolly Best Doctor and as one of New York Magazine's Best Doctors.
Dr. Prenner has published 75 papers in the peer-reviewed literature in addition to a volume of textbook chapters, articles and scientific abstracts. He lectures routinely at major scientific meetings concerning his original research and the development of new approaches to vitreoretinal diseases. He has delivered dozens of invited lectures on retinal research across the United States and internationally, and has been an invited member of the American Academy of Ophthalmology subspecialty day faculty five times. He is the Principal Investigator for numerous international multi-center clinical trials evaluating new treatments for retinal diseases including age-related macular degeneration.
Dr. Prenner received his undergraduate degree from the University of Pennsylvania and his medical doctor degree from the State University of New York at Stony Brook. He was accepted into the Alpha Omega Alpha Honor Society and served as its president there. He was also president of the student chapter of the American Medical Association at SUNY. Dr. Prenner then returned to the University of Pennsylvania's Scheie Eye Institute for residency training in ophthalmology, where he was appointed chief resident. He then completed a two-year vitreoretinal fellowship at William Beaumont Hospital, Royal Oak, Michigan, one of the premier retina training programs in the country. At Beaumont, he was awarded two national honors, the Heed Ophthalmic Fellowship Award and the Ronald G. Michels Retinal Fellowship. Dr. Prenner joined NJ Retina in 2004.
Dr. Prenner is Board Certified in Ophthalmology. He is a member of the Macula Society, Retina Society, American Academy of Ophthalmology, American Society of Retina Specialists, Society of Heed Fellows, Alpha Omega Alpha, ARVO, Club Vit, and the Buckle Vit Society. He serves as a manuscript referee for Ophthalmology, the Journal of the American Academy of Ophthalmology, Retina, The Journal of Retinal and Vitreous Diseases, and the British Journal of Ophthalmology. He has also edited recurring series in both Retina Times and Review of Ophthalmology. He maintains special interests in complicated retinal detachment, secondary intraocular lens surgery, diabetic eye disease, and age-related wet macular degeneration.
1. Describe the impact of the Medicare Access and CHIP Reauthorization Act (MACRA) on ophthalmology and its potential impact on the prescribing of anti-VEGF agents.
2. Discuss the potential impact of the Drug Quality and Security Act and opportunities to advocate for continued access to compounded ophthalmologic drugs.

Program Overview: The introduction of anti-VEGF agents for the treatment of age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO), transformed the management of these conditions. While the clinical benefits of these compounds are well documented their use brings up other issues for ophthalmologists, namely, cost. Thus, payers have become more involved in managing the use of these agents, potentially interfering with clinical decision making. 
 
ACCREDITATION STATEMENT
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
CREDIT DESIGNATION STATEMENT
Evolve Medical Education LLC designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
 
The following faculty/staff members have the following financial relationships with commercial interests:
David Eichenbaum, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences; Allergan plc; Genentech; Notal Vision; and Regeneron Pharmaceuticals, Inc. Grant/Research Support: Alcon; Allergan plc.; Clearside Biomedical; Genentech; Novartis; and Opthotech. Speaker’s Bureau: Allergan plc; Genentech; and Notal Vision. Stock/Shareholder: BIRC, Clearside Biomedical; Humera; and US Retina.
 
Jonathan L. Prenner, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon; Genentech; and Regeneron Pharmaceuticals, Inc.
 
EDITORIAL SUPPORT DISCLOSURES
Erin K. Fletcher, MIT, director of compliance and education, Susan Gallagher-Pecha, director of client services and project management, Evolve; and Debra Gordon, MS, writer, have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has no financial relationships with commercial interests.
 
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Regeneron Pharmaceuticals, Inc.
 
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
GRANTOR STATEMENT
Supported through an educational grant from Regeneron Pharmaceuticals, Inc.
 
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
 
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.